Raise closed, search for fresh raises on Seedstage

Princeton, NJ

Advancing clinical trials for innovative cancer therapies to improve treatment options for rare cancers.

• Cutting-edge therapies: Developing next-generation chemotherapeutic agents targeting rare and life-threatening cancers.
• Advanced clinical trials: One drug in Phase 3 trials and two others ready to advance to Phase 3.
• Strategic partnerships: Collaborations with global pharmaceutical firms enhance market reach and financial support.
• Regulatory advantages: Supported by orphan drug designations providing market exclusivity in key regions.
• Expert leadership: A team with extensive experience in life sciences and clinical-stage therapeutics development.

Eleison Pharmaceuticals is advancing next-generation chemotherapeutic agents to address rare and life-threatening cancers, including pancreatic, lung, and brain cancers. The company is committed to delivering safer, more effective cancer treatments by leveraging innovative formulations designed to target tumors with greater specificity and reduced toxicity. With one drug candidate currently in a Phase 3 clinical trial and two others ready for Phase 3, Eleison is poised to address critical gaps in cancer care for patients with limited treatment options. The company aims to use the funds raised to support ongoing and future clinical trials, regulatory submissions, and strategic commercialization efforts.

Eleison Pharmaceuticals’ approach is built on a robust intellectual property portfolio, partnerships with leading pharmaceutical firms, and a seasoned team of experts with decades of experience in life sciences. The company’s development pipeline is supported by orphan drug designations, ensuring market exclusivity and regulatory advantages in key markets. Eleison’s ultimate goal is to bring innovative therapies to market that can significantly improve patient outcomes while addressing substantial unmet medical needs in the oncology sector.

Company Info

Eleison Pharmaceuticals develops advanced chemotherapies for rare cancers, with three drug candidates in late-stage clinical trials.

Eleison Pharmaceuticals is focused on advancing next-generation chemotherapies designed to address rare and life-threatening cancers, including pancreatic, small-cell lung, and brain cancers, which have limited treatment options. The company’s primary goal is to develop drugs that target cancer cells more effectively, reducing toxicity compared to traditional chemotherapy treatments. With a strong portfolio of drug candidates, including Glufosfamide, ILC (Inhaled Lipid-Complexed Cisplatin), and DBD (Dibromodulcitol), Eleison aims to improve treatment outcomes for patients with these hard-to-treat cancers. All three drug candidates are in Phase 3 clinical trials or are Phase 3 ready, with a focus on obtaining regulatory approval through New Drug Applications (NDAs).

Eleison Pharmaceuticals is supported by a robust intellectual property portfolio, including over 60 patents and orphan drug designations in the U.S. and Europe, which provide regulatory advantages and market exclusivity. The company has established key partnerships with pharmaceutical companies, such as Daewoong Pharma (South Korea), Intelgen (China), and Rafa Laboratories (Israel), to support global drug development efforts. Eleison’s projected timeline for regulatory submissions and commercialization is set between 2026 and 2029, with anticipated peak annual revenues ranging between $1–5 billion for its lead drug candidates. The company’s approach to oncology drug development aims to make a significant impact in the multi-billion-dollar cancer treatment market.